

SuperQ Quantum Enters Commercial Agreement to Deploy Quantum-AI Clinician Systems for Science & Humans

Calgary, Canada - November 4th, 2025 - [SuperQ Quantum Computing Inc.](#) (“**SuperQ Quantum**”, “**SuperQ**”, or the “**Company**”) (CSE: QBTQ; Frankfurt: 25X; OTCQB: QBTQF), has entered into a commercial agreement with [Science & Humans](#) (“S&H”), a Canadian hormonal health company and a recipient of the **Deloitte Technology Fast 50** recognition in 2025, to deploy quantum-AI powered clinician solutions for S&H. Under the agreement, SuperQ will architect and deliver AI clinicians enhanced by quantum computing based optimization for S&H to integrate into its real-world healthcare workflows.

Addressing Challenges of Increased Clinical Demands

S&H is an Ontario-based provider of hormonal healthcare including menopause, thyroid conditions, sexual health and more. It has been experiencing significant user growth and is one of the [Deloitte’s Technology Fast 50](#) companies this year. S&H requires autonomous systems such as diagnostic and treatment AI to keep up with the increased demand. High accuracy and speed are key considerations for this sensitive life sciences use case. S&H’s scientific and clinical teams are providing the domain expertise and knowledge base for these systems.

SuperQ is building these systems for S&H through its professional services and Super™ platform, which enables development of quantum-AI products. Super™ implements interoperability across quantum hardware types (annealing, gate-based, hybrid classical/quantum) and integrates high-performance classical compute, AI-driven orchestration and quantum processing. This “gateway” approach enables enterprises and healthcare institutions to leverage emerging quantum architectures along with GPU-based AI pipelines without being locked into a single hardware ecosystem.

Aftab Pashaw, CEO of S&H, commented: “We are excited to be the first to explore frontier AI and quantum technologies in clinical diagnosis and treatment. SuperQ is playing a key role in the development, integration and enhancement of our clinical AI systems. Together, we have already reached the MVP stage and aim to reach full production in the coming months.”

Strategic Implications in the Backdrop of NVIDIA Announcements

The recent unveiling of [NVIDIA’s NVQLink](#) interconnect at NVIDIA GTC DC marks a pivotal shift in how quantum and classical compute infrastructure will collaborate, a shift that directly amplifies the strategic value of SuperQ’s Super™ platform. NVIDIA is now doing at the hardware level what SuperQ has been doing at the software level - interlacing classical and quantum computing to create real-world value.

The “[Quantum, AI and High-performance Computing: intersection Opportunities](#)” meetup organized by Dr. Khan at the NVIDIA GTC explored this coupling in detail. The participants agreed that we have entered a hybrid classical-quantum reality. NVIDIA’s hardware announcements reinforce SuperQ’s vision of driving commercial value from hybrid compute. Super™ gateway platform is purpose-built to orchestrate classical compute, AI pipelines and multiple quantum



hardware types (annealing, gate-based, hybrid), especially in sensitive industries like healthcare where reliability, interpretability and speed are non-negotiable.

“Commercial use cases for the Super™ platform and related professional services are growing by the day,” said Dr. Muhammad Khan, CEO & Board Chair of SuperQ. “The Science & Humans project signals that quantum-AI is now ready to transform clinician workflows, where the margin for error is minimal and the stakes are highest.”

Project Highlights

SuperQ will architect and deliver quantum-AI clinician systems in domains where accuracy, interpretability and reliability are paramount - including patient triage, autonomous monitoring, treatment optimisation and decision-support in sensitive care environments.

The initial roadmap entails a **phased-deployment approach**:

1. Triageing patients and enhancing diagnostic decision-support.
2. Streamlining prescription workflows.
3. Extending into chronic disease management, real-time patient monitoring and broader healthcare-system logistics.

Science & Humans brings recognised clinical and scientific domain strength to the collaboration. Notably, Science & Humans was ranked No. 32 on Deloitte Canada’s 2025 Technology Fast 50 list, reflecting 970% growth over the prior three years.

This agreement complements SuperQ’s recent hardware-and-software roadmap expansion, including the launch of its Super™ hybrid quantum-classical platform and the initiation of quantum-hardware development - positioning SuperQ as one of the few, if not the first, bridging quantum-AI architecture with commercial-healthcare solutions.

About SuperQ Quantum Computing Inc.

SuperQ Quantum Computing Inc. (CSE: QBTQ; Frankfurt: 25X; OTCQB: QBTQF) is defining the next era of enterprise transformation, looking to emerge as a partner for global organizations seeking direct quantum and supercomputing ROI previously beyond reach. We are looking to position ourselves as the trusted leader in quantum and supercomputing-powered problem-solving and optimization.

Our flagship Super™ platform strives to make the most advanced computational power intuitive and accessible. This will empower executives, leading research institutions, and critical government agencies to unlock immediate business impact across finance, healthcare, logistics, defense, and beyond, leveraging our proprietary AI Autopilots to turn complex challenges into executive-ready results with one-click productization and deployment. SuperQ Quantum is headquartered in Canada with a growing international presence, particularly in the US, Middle East and Asia, strategically establishing Super Hubs in key regions.

For further information contact:

Dr. Muhammad Khan, CEO of SuperQ Quantum Computing Inc.



Email: info@superq.co

Telephone: +1 587 889 1918

www.superq.co

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer's business, capital, or operations that is prospective in nature. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking information. Forward-looking information is often identified by terms such as "may", "should", "anticipate", "would", "will", "estimates", "believes", "intends" "expects" and similar expressions which are intended to identify forward-looking information. More particularly and without limitation, this press release contains forward-looking information concerning statements with respect to the closing of the Offering, timing of closing of the Offering, the use of proceeds of the Offering and the future plans of the Company. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions, expectations and risks, many of which are beyond the control of the Company, including but not limited to assumptions regarding prevailing market conditions and general business, economic, competitive, political and social uncertainties to develop the forward-looking information in this press release, as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.com. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.

The forward-looking information contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.